Medical Equipment/Supplies/Accessories · Founded 1994 · www.krettosysconltd.com · BSE 531328 · · ISIN INE128R01023
No Notes Added Yet
Business
Kretto Syscon Ltd. (formerly Kretto Forex Ltd.) is primarily engaged in the trading, distribution, and supply of various medical equipment, devices, and accessories within India. The company acts as a vital link between manufacturers (both domestic and potentially international) and end-users in the healthcare sector, which include hospitals, clinics, diagnostic centers, and other medical institutions. Its core business model involves sourcing a diverse range of medical products and distributing them through its network. The company generates revenue through the sales of these medical products.
Revenue Mix
Given its primary business as a trader and distributor of medical equipment, Kretto Syscon Ltd. likely does not operate with formally segmented business units in the same way a manufacturing company would. Its revenue mix would largely comprise sales across different categories of medical devices, instruments, and consumables (e.g., diagnostic equipment, surgical tools, patient monitoring systems, disposables). Specific breakdowns of revenue contribution by product category are not typically disclosed for companies of this nature without detailed financial reports.
Industry
The Indian medical equipment market is experiencing significant growth, driven by increasing healthcare expenditure, expansion of medical infrastructure, a rising disease burden, and government initiatives. This market is highly fragmented, featuring large multinational corporations (MNCs) with advanced proprietary products, domestic manufacturers, and a multitude of distributors and traders. Kretto Syscon Ltd. likely positions itself as a regional or niche distributor, competing on factors such as product availability, pricing, supply chain efficiency, and existing customer relationships rather than proprietary technology or dominant brand recognition. It operates within the mid-to-lower tier of the supply chain, facilitating access to a variety of medical products for healthcare providers.
MOAT
As a trading and distribution company, Kretto Syscon Ltd. is unlikely to possess strong, durable competitive advantages typically associated with high-tech manufacturers (e.g., patents, proprietary technology, strong brand equity). Potential, albeit weaker, advantages could include:
Established Distribution Network: Relationships with a network of healthcare providers and an efficient logistics system.
Product Portfolio Diversity: Ability to offer a wide range of products from multiple suppliers, providing a 'one-stop shop' for some customers.
Customer Relationships: Long-standing rapport and trust built with key healthcare institutions.
These advantages are generally replicable and do not constitute a wide, enduring economic moat.
Growth Drivers
Increasing Healthcare Spending: Growth in public and private investment in healthcare across India.
Expansion of Healthcare Infrastructure: Development of new hospitals, clinics, and diagnostic centers, particularly in tier-2 and tier-3 cities.
Rising Incidence of Chronic Diseases: Drives demand for diagnostic and treatment equipment.
Medical Tourism: Boosts demand for high-quality medical devices and services.
Technological Advancements in Medical Devices: While not a developer, the company benefits from distributing newer, more sophisticated equipment.
Risks
Intense Competition: Highly fragmented market with numerous domestic and international competitors, leading to pricing pressures.
Dependency on Suppliers: Reliance on a limited number of manufacturers for product supply, pricing, and availability.
Regulatory Changes: Evolving government regulations regarding medical device pricing, import duties, quality standards, and approval processes can impact profitability.
Supply Chain Disruptions: Global and local logistics challenges, geopolitical events, or pandemics can affect product sourcing and delivery.
Technological Obsolescence: Rapid advancements in medical technology could render existing product lines less competitive, impacting inventory value.
Working Capital Management: As a trading company, efficient management of inventory and receivables is crucial to maintain liquidity.
Management & Ownership
Kretto Syscon Ltd. is a promoter-led company. The ownership structure typically features a significant stake held by the promoter group, with the remaining shares held by the public and institutional investors. The company's management is responsible for strategic direction, procurement, sales, and operational efficiency within the highly competitive medical equipment distribution sector. Specific details on the individual promoters' extensive professional track records or qualifications are not readily summarized in general public disclosures for SME-listed entities.
Outlook
Kretto Syscon Ltd. operates in a promising sector poised for substantial growth in India's expanding healthcare landscape. The company's ability to capitalize on increasing demand for medical equipment, expand its distribution network, and maintain strong supplier and customer relationships could drive future growth. However, the outlook is tempered by the intense competition, often low-margin nature of distribution, and vulnerability to regulatory shifts and supply chain volatility inherent in the medical device trading industry. The lack of proprietary products or strong brand differentiation makes the company susceptible to competitive pressures and limits its pricing power. Sustainable profitability will depend on its operational efficiency, effective working capital management, and agility in navigating a dynamic and competitive market.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 0 | 1 | 6 | 2 | 3 | 4 | 0 | 0 | 1 | 0 |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income | 0 | 1 | 6 | 2 | 3 | 4 | 1 | 0 | 1 | 0 |
| Total Expenditure | 0 | 0 | 1 | 0 | 5 | 1 | 1 | 0 | 1 | 0 |
| Operating Profit | 0 | 1 | 5 | 1 | -2 | 3 | 0 | 0 | -0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 1 | 5 | 1 | -2 | 3 | 0 | 0 | -1 | 0 |
| Provision for Tax | 0 | 0 | 1 | 0 | -0 | 1 | 0 | 0 | -0 | 0 |
| Profit After Tax | 0 | 1 | 4 | 1 | -1 | 2 | 0 | 0 | -0 | 0 |
| Adjustments | -0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 0 | 1 | 4 | 1 | -1 | 2 | 0 | 0 | -0 | 0 |
| Adjusted Earnings Per Share | 0 | 0 | 0.2 | 0 | -0 | 0 | 0 | 0 | -0 | 0 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 0 | 6 | 5 | 2 | 1 | 0 | 0 | 3 | 0 | 0 | 11 | 1 |
| Other Income | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 0 |
| Total Income | 0 | 7 | 6 | 3 | 1 | 0 | 1 | 4 | 1 | 1 | 12 | 2 |
| Total Expenditure | 0 | 6 | 5 | 3 | 1 | 0 | 0 | 4 | 0 | 0 | 6 | 2 |
| Operating Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | -1 |
| Provision for Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Profit After Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 |
| Adjusted Earnings Per Share | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | 0 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 0% | 54% | 0% | 0% |
| Operating Profit CAGR | 0% | 0% | 0% | 0% |
| PAT CAGR | 0% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -73% | -10% | -5% | -20% |
| ROE Average | 10% | 4% | 3% | 2% |
| ROCE Average | 13% | 6% | 4% | 2% |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 16 | 16 | 15 | 16 | 16 | 16 | 16 | 16 | 16 | 17 | 68 |
| Minority's Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 0 | 4 | 3 | 4 | 1 | 1 | 1 | 2 | 1 | 2 | 2 |
| Total Liabilities | 16 | 20 | 18 | 19 | 17 | 17 | 17 | 18 | 18 | 19 | 71 |
| Fixed Assets | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Other Non-Current Assets | 16 | 14 | 16 | 15 | 16 | 16 | 17 | 17 | 16 | 18 | 58 |
| Total Current Assets | 0 | 6 | 2 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 12 |
| Total Assets | 16 | 20 | 18 | 19 | 17 | 17 | 17 | 18 | 18 | 19 | 71 |
| #(Fig in Cr.) | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow from Operating Activities | -15 | 0 | 3 | -1 | -0 | -0 | 0 | 0 | 0 | -0 | -3 |
| Cash Flow from Investing Activities | 0 | 0 | -2 | 1 | -0 | 0 | 0 | 0 | -0 | 0 | -40 |
| Cash Flow from Financing Activities | 15 | -0 | -1 | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 47 |
| Net Cash Inflow / Outflow | 0 | -0 | 0 | 0 | -0 | -0 | 0 | 0 | 0 | -0 | 4 |
| Closing Cash & Cash Equivalent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 |
| # | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | 0 | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0.01 | 0.01 | 0.01 | 0.01 | 0.06 |
| CEPS(Rs) | 0 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.07 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | 0.66 | 0.67 | 0.68 | 0.69 | 0.7 | 0.7 | 0.71 | 0.72 | 0.73 | 0.74 | 1 |
| Core EBITDA Margin(%) | 3.98 | -8.28 | -13.72 | -25.77 | -64.18 | 0 | 0 | -12.28 | 0 | 0 | 44.31 |
| EBIT Margin(%) | 3.98 | 3.33 | 6.8 | 13.48 | 48.82 | 0 | 0 | 7.01 | 0 | 0 | 50.91 |
| Pre Tax Margin(%) | 3.84 | 3.33 | 6.8 | 13.48 | 48.77 | 0 | 0 | 6.95 | 0 | 0 | 50.89 |
| PAT Margin (%) | 2.65 | 2.3 | 4.7 | 9.31 | 35.93 | 0 | 0 | 5.14 | 0 | 0 | 37.66 |
| Cash Profit Margin (%) | 2.65 | 2.3 | 4.7 | 9.31 | 38.08 | 0 | 0 | 5.23 | 0 | 0 | 37.72 |
| ROA(%) | 0.13 | 0.76 | 1.15 | 1.15 | 1.01 | 0.65 | 0.69 | 1.01 | 1.06 | 1.41 | 9.28 |
| ROE(%) | 0.16 | 0.91 | 1.46 | 1.41 | 1.17 | 0.7 | 0.74 | 1.1 | 1.15 | 1.53 | 9.77 |
| ROCE(%) | 0.2 | 1.24 | 2.05 | 2.04 | 1.59 | 0.95 | 1 | 1.51 | 1.55 | 2.07 | 12.9 |
| Receivable days | 8.45 | 173.28 | 219.57 | 209.3 | 1028.53 | 0 | 0 | 0 | 0 | 0 | 252.58 |
| Inventory Days | 0 | 0 | 106.36 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Payable days | 20.83 | 116.9 | 260.41 | 449.05 | 1665.16 | 0 | 0 | 107.95 | 0 | 0 | 12.31 |
| PER(x) | 0 | 171.39 | 1120.8 | 210.68 | 60.82 | 42.48 | 68.11 | 86.92 | 44.27 | 49.97 | 27.92 |
| Price/Book(x) | 0 | 1.56 | 16.18 | 2.95 | 0.7 | 0.29 | 0.5 | 0.95 | 0.51 | 0.76 | 1.7 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 23.2 | 3.98 | 52.61 | 19.44 | 21.22 | 0 | 0 | 4.39 | 0 | 0 | 10.28 |
| EV/Core EBITDA(x) | 582.94 | 119.35 | 773.23 | 144.15 | 41.64 | 29.74 | 48.09 | 61.66 | 30.56 | 38.04 | 20.18 |
| Net Sales Growth(%) | 43.79 | 1268.81 | -20.94 | -50.29 | -78.21 | -100 | 0 | 0 | -100 | 0 | 0 |
| EBIT Growth(%) | 806.18 | 1046.12 | 61.44 | -1.5 | -21.11 | -39.73 | 7.14 | 52.06 | 3.9 | 39.57 | 1479.63 |
| PAT Growth(%) | 560.59 | 1088.54 | 61.33 | -1.46 | -15.95 | -39.8 | 7.96 | 50.3 | 5.11 | 35.4 | 1526.17 |
| EPS Growth(%) | 108.22 | 1089.1 | 61.29 | -1.42 | -15.96 | -39.8 | 8.02 | 50.22 | 5.11 | 35.4 | 442.06 |
| Debt/Equity(x) | 0 | 0.02 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.06 | 0.01 |
| Current Ratio(x) | 2.04 | 1.4 | 0.54 | 0.88 | 0.53 | 0.09 | 0.13 | 0.18 | 0.41 | 0.04 | 7.22 |
| Quick Ratio(x) | 2.04 | 1.4 | 0.1 | 0.88 | 0.53 | 0.09 | 0.13 | 0.18 | 0.41 | 0.04 | 7.22 |
| Interest Cover(x) | 28.02 | 0 | 1446.33 | 2808.73 | 1019.24 | 581.81 | 585.16 | 105.37 | 1396.15 | 31.31 | 3491.75 |
| Total Debt/Mcap(x) | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.08 | 0.01 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 15.68 | 15.68 | 15.68 | 62.72 | 62.72 | 62.72 | 67.73 | 67.73 | 67.73 | 67.73 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15.68 | 15.68 | 15.68 | 62.72 | 62.72 | 62.72 | 67.73 | 67.73 | 67.73 | 67.73 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | — | +54% | — | — |
| Operating Profit CAGR | — | — | — | — |
| PAT CAGR | — | — | — | — |
| Share Price CAGR | -73% | -10% | -5% | -20% |
| ROE Average | +10% | +4% | +3% | +2% |
| ROCE Average | +13% | +6% | +4% | +2% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 15.68 | 15.68 | 15.68 | 62.72 | 62.72 | 62.72 | 67.73 | 67.73 | 67.73 | 67.73 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 15.68 | 15.68 | 15.68 | 62.72 | 62.72 | 62.72 | 67.73 | 67.73 | 67.73 | 67.73 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.